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It Is Not Simple Anymore*Robert O. Bonow, MD, MSSEE PAGE 2827F or decades, and until very recently, managingasymptomatic patients with aortic stenosis(AS) seemed to be a relatively simple and
straightforward process: one merely had to wait for
the onset of symptoms, at which point it was reason-
able to recommend aortic valve replacement (AVR).
This was based on the conceptual framework pro-
posed by Ross and Braunwald in their seminal paper
in 1968 (1), which postulated that the natural history
of AS involves a long asymptomatic, latent period of
increasing valve obstruction and left ventricular pres-
sure overload, during which there are few morbid
events, followed ultimately by the onset of symptoms
that herald a predictable high mortality rate.
Initially based on astute clinical observations in
only a handful of patients, this concept was
conﬁrmed over the next 40 years by subsequent
studies showing that roughly 50% of symptomatic
patients treated without surgery died over the course
of the next 2 to 3 years (2–4). However, asymptomatic
patients—even those with severe stenosis—seemed to
have a low mortality risk. Although patients with
severe AS (deﬁned as a peak aortic velocity [Vmax] of
>4 m/s) had a high event rate within 5 years, the
events were primarily onset of symptoms and not
sudden death (5–9). Otto et al. reported no deaths in
123 asymptomatic individuals followed for a mean of
2.5 years (5); the 6 patients who died had developed
symptoms and were either awaiting surgery or
declined surgery. In a series of 116 asymptomatic
patients with very severe AS (Vmax of $5 m/s) re-
ported by Rosenhek et al. (9), only 1 of 6 deaths was*Editorials published in the Journal of the American College of Cardiology
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(6 patients) died within 3 months of undergoing AVR,
so the short-term surgical risk was equivalent to the
risk of waiting. These data suggest that AVR is
inevitable within a few years among patients with
severe AS, but is unlikely to improve survival if
patients can be followed carefully for onset of
symptoms. This has major implications in elderly
patients for whom the risks of mortality, morbidity,
and quality of life after AVR are not inconsequential.
However, not all studies paint such a benign picture
of asymptomatic severe AS, with reports of signiﬁcant
mortality rates among elderly patients, particularly
those with progressively severe AS (10–12). Interpret-
ing these retrospective studies is difﬁcult because
many of the deaths occurred in individuals who had
become symptomatic and it is unclear how carefully
seemingly asymptomatic patients were followed.
Moreover, interpreting the lack of symptoms remains
notoriously difﬁcult in a population that is becoming
increasing older and deconditioned; it is also well-
known that patients downregulate their activity level
to avert symptoms. This has stimulated interest in
circulating biomarkers as more objective markers of
disease progression (13,14), but deﬁnitive studies are
lacking. The uncertainty regarding whether asymp-
tomatic patients with a certain severity of AS should
undergo surgery now or surgery later has created an
equipoise that can only be addressed by a well-
designed prospective, randomized clinical trial.In the absence of such a trial evaluating surgery
versus watchful waiting for asymptomatic severe AS,
the study by Taniguchi et al. (15) in this issue of
the Journal is about as good as it gets in shedding
more light on this issue. The strengths of the study
include: 1) well-matched patients using propensity
scoring; 2) the intention-to-treat analysis; 3) event
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sentation of outcomes of all patients as well as those
included in the propensity analysis; and 5) the fact
that 63% of asymptomatic patients undergoing sur-
gery at presentation had 1 or more of the objective
guidelines indications for AVR (16). The signiﬁcantly
lower event and mortality rates in the surgical group
(despite greater AS severity) is an important clinical
observation for the cardiology community and will
spark ongoing discussion about management of these
patients. The other ﬁnding worthy of attention, as
noted by the authors, is that 41% of patients managed
conservatively (if they survived) required AVR within
a median follow-up of 2 years, conﬁrming the results
of earlier studies (5–9). Thus, one does not gain much
by waiting.
Taniguchi et al. (15) have discussed carefully the
limitations inherent in a retrospective study requiring
propensity analysis. Nonetheless, their data raise
important questions. The deﬁnition of severe AS
(Vmax >4 m/s, mean gradient >40 mm Hg or aortic
valve area <1.0 cm2) leaves open the possibility that
many patients were included on the basis of aortic
valve area of <1.0 cm2 alone with less severe Vmax and
mean gradient. It is apparent that more than one-
third of patients in the conservatively managed
group had a Vmax of <4 m/s (Table 1 of Taniguchi
et al. [15]). These patients may indeed have had truly
severe AS (with normal left ventricular function and
paradoxic low gradient [17]), but the imprecision of
assessing aortic valve area by echocardiography with
possible overestimation of AS severity in some pa-
tients causes some uncertainty. Additionally, it is
particularly noteworthy that 51% of patients in the
total group of patients treated conservatively who
became symptomatic did not undergo AVR, including
36 of 116 (31%) patients who became symptomatic in
the propensity-matched conservative group, of whom
17 died. These ﬁndings, conﬁrming the expected pooroutcome of symptomatic patients who did not un-
dergo AVR, undoubtedly contributed to the observed
worse survival compared with the initial surgical
group. Whether the conservatively treated patients
would have fared better if prompt recognition of
symptoms led to appropriate referral for AVR is un-
known. There are also traditional customs in some Far
Eastern cultures that may have led to certain patients
declining surgery, even if it was recommended.
Thus, the observations of Taniguchi et al. (15)
provide additional insights into outcomes of asymp-
tomatic patients with severe AS, including those who
become symptomatic, but do not obviate the need for
a prospective clinical trial comparing AVR with con-
servative management. The true value of an early
AVR strategy can only be determined by such a trial.
Despite improving AVR outcomes in elderly patients
(18,19), the risks and discomforts of surgical AVR will
pose difﬁculties in enrolling asymptomatic elderly
patients. This provides a unique opportunity for
transcatheter AVR, which may stimulate greater
physician and patient buy-in for enrollment than a
trial involving surgical AVR.
In his 1958 Nathanson Lecture, Dr Paul Wood
argued prophetically that “aortic stenosis is a simple
mechanical fault which, if severe enough, imposes a
heavy burden on the left ventricle and sooner or later
overcomes it” (20). The burden of AS on the left
ventricle remains true today, but what has changed is
that AS management is no longer simple. The time
has come for a prospective randomized trial to ﬁnally
provide the deﬁnitive evidence that will inform
future practice.
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